

Cardiomiopatie hot topics

Cardiomiopatia e extrasistolia ventricolare: puntualizzazione diagnostica e indicazioni al trattamento

Federico Ferraris




Premature
Ventricular
Complex

Cardio
Myopathy

Tachy Cardio
Myopathy

Tachy Cardio Myopathy

Incidence




~ 3% HF pts referred for cardiac ablation had EF normalization after the procedure


Donghua *J Interv Card Electrophysiol* 2013

Gopinathannair R. et al., *J Am Coll Cardiol*, 2015

Hasdemir C. et al., *Anatol J Cardiol*, 2019


Yokokawa M. et al., *Heart Rhythm*, 2013






>>>> Prospective study >>>>


Ex juvantibus



Ex juvantibus



Prior to PVC ablation



93 pts
Burden >
4%

2010-2015
RF for PVC




Mean EF 34%

Ablation


1 year followup

PVC ablation

Improvement in TCM and NICM



Prior to PVC ablation



93 pts

2010-2015
RF for PVC

Burden >
4%


Mean EF 34%

Ablation

1 year followup

Retrospective

PVC ablation in cardiomyopathy



93 pts
2010-2015
RF for PVC
Burden > 4%
Mean EF 34%

Ablation

1 year followup

Predictors of NICM

	Univariate		Multivariate	
	OR (95% CI)	P value	OR (95% CI)	P value
Sex (male)	0.78 (0.33–1.8)	.57		
Age	0.99 (0.96–1.04)			
LVEF (%)	0.97 (0.91–1.03)	.63		
PVC burden (%)	0.82 (0.76–0.89)	<.001*	0.7 (0.5–0.84)	<.001
BNP (pg/mL)	0.99 (0.99–1.01)	.47		
Location (left ventricle)	0.45 (0.17–1.14)	.09*		
QRS >130 ms	50 (1.3–221)	.002*	50 (1.3–1991)	.036
LVEDD (mm)	1.09 (0.99–1.2)	.06*	1.66 (1.2–2.27)	.01
CMR scar	2.3 (0.23–23.5)	.48		
>1 PVC morphology	0.237 (0.6–0.94)			
NYHA functional class	0.75 (0.35–1.6)			

PVC burden cutoff < 17%


LVEDD cutoff 67 mm

TCM


PVC

**EF
reduction**


Algorithm




NICM



**TachyCardio
Myopathy**





Retrospective

PVC ablation in cardiomyopathy

168 PVC patients referred for PVC ablation

**Group 1:
suspected TCM**

EF < 50% and
no CMP sign

**Group 2:
no TCM**

Normal EF and
no LV dilation

Ablation

EF normalization if
ablation successful

PVC Cardiomyopathy is not tachycardia related

Lack of palpitations

High PVC burden

Epicardial Origin

PVC Coupling interval


Holter mean heart rate

Bigeminism or Trigeminiism

Post PVC pause


Physyopathology



Animal Studies





Not rate dependent

Variable response







Retrospective

PVC ablation in cardiomyopathy

Table 1 Clinical and ECG characteristics of the patients populations

PVC CMP predictors

Lack of palpitations

PVC burden

Epicardial Origin

PVC CMP NON predictors

PVC Coupling interval

Holter mean heart rate

Bigeminism or Trigemism

Post PVC pause

Retrospective

PVC ablation in cardiomyopathy

Table 1 Clinical and ECG characteristics of the patients populations

	Group 1 (n = 158)
Class I	30 (35%)
Calcium channel blockers	19 (11%)
Sotalol	10 (6%)
Lack of palpitations	
PVC burden (%)	22 ± 13
PVC burden ≤ 10%	31 (10%)
PVC burden	
Sinus QRS amplitude (mV)	1.63 ± 0.67
Sinus QRS duration (ms)	104 ± 30
Epicardial Origin	
18 LS (12%)	

	Group 1 (n = 96)	Group 2 (n = 72)	P-value
PVC CMP NON predictors			
PVC Coupling interval	16 (16%)	28 (28%)	.001
Holter mean heart rate	6 (6%)	13 (18%)	
Bigeminism or Trigeminiism	3 (3%)	7 (10%)	
Post PVC pause	17%	0%	
113 ± 245	1084 ± 265	.5	
14 ± 29	6 ± 18	.04	

Retrospective

PVC ablation in cardiomyopathy

Table 1 Clinical and ECG characteristics of the patients populations

	Group 1 (n = 96)	Group 2 (n = 72)	P-value
PVC CMP predictors			
Lack of palpitations			
PVC burden			
Epicardial Origin			
PVC CMP NON predictors			
PVC Coupling interval			
Holter mean heart rate			
Bigeminism or Trigeminiism			
Post PVC pause			

174 PVC pts
referred for
ablation

Reduced EF in 33%

Treatment → ef recovery

Burden cutoff TMC 24%


No TCM for burden < 10%

PVC burden

**Intra patient
variability**

Burden


Intra patient variability



PVC burden


Intra patient
variability

Natural history



Prospective

Reduction over time



100 PVC pts

Burden > 5% (mean 18%)


Normal MRI

29 months followup


4% developed TMC –
all high burden (11-26%)

PVC burden

Intra patient
variability



Reduction over
time



Threshold

174 PVC pts
referred for
ablation

Reduced EF in 33%


Treatment → ef recovery

Burden cutoff TMC 24%

No TCM for burden < 10%

CPV Burden

Threshold determination



174 PVC pts
referred for
ablation


Reduced EF in 33%

Burden cutoff
TMC **24%**


No TCM for
burden **< 10%**

PVC burden


Intra patient
variability



Reduction over
time



Weak
correlation




PVC

Practical approach

Rule out Structural
Cardiomyopathy

Structural abnormal heart

Structural normal heart



Zeppenfeld, 2022 ESC Guidelines on
ventricular arrhythmias and SCD

PVC

Practical approach

Assessment

Inconclusive or atypical presentation^b

CMR (Class IIa)

Structural abnormal heart

Structural normal heart

Catheter ablation
(Class IIb)


Beta-blockers,
CCB or
Flecainide
(Class IIa)

Flecainide
(Class IIa)
Catheter ablation
(Class IIa)

Older age
RBB morphology
Reentry SVT

PVC structural disease

Practical approach



Burden > 10% and reduced EF

Sinus QRS > 130 ms


LVEDD > 67 mm

Burden < 17%

Zeppenfeld, 2022 ESC Guidelines on ventricular arrhythmias and SCD


PVC

Practical approach



PVC no structural disease

Practical approach





Structural normal heart

Zeppenfeld, 2022 ESC Guidelines on ventricular arrhythmias and SCD

PVC no structural disease

Practical approach



Conclusions

PVC **sign** of
cardiomyopathy

PVC **cause** of
cardiomyopathy

PVC **worsen**
cardiomyopathy

Dissincrony

Burden


Treat if:

Symptoms

EF reduction and
burden $> 10\%$


Consider treatment
burden $> 20\%$

Followup




AI


CENTRAL ILLUSTRATION: Deep Learning to Predict Cardiomyopathy in Patients With PVCs



CENTRAL ILLUSTRATION: Deep Learning to Predict Cardiomyopathy in Patients With PVCs




CENTRAL ILLUSTRATION: Deep Learning to Predict Cardiomyopathy in Patients with PVC



A

ROC Curve




25.995 ECG with PVC

FE <40% within 6 months


Table 3. Multivariable Cox Regression Model for the Outcome of LVEF $\leq 40\%$

	HR	95% CI	P Value
Algorithm predicting cardiomyopathy	304.1	77.2-1,197.5	<0.01
PVC burden	1.42	1.3-1.6	<0.01
Age	0.78	0.71-0.85	<0.01
Male	1.6	1.2-2.0	<0.01


CENTRAL ILLUSTRATION: Deep Learning to Predict Cardiomyopathy in Patients With PVCs




CENTRAL ILLUSTRATION: Deep Learning to Predict Cardiomyopathy in Patients With PVCs



GradCAM Explainability



and ST-segment in red.



model prediction.